Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced positive results from a Phase III study for its drug MRX-4 in combination with contezolid as sequential therapy for complex skin and soft tissue infections. The study successfully met its primary efficacy endpoint, demonstrating good clinical and microbiological efficacy. The regimen’s clinical efficacy was found to be non-inferior to linezolid, a standard treatment in this area.
Clinical Efficacy and Safety Profile
The study highlighted the good safety and tolerability profile of the MRX-4/contezolid combination, with no adverse events related to the investigational drug leading to discontinuation of treatment or withdrawal from the study. This is a significant milestone for the drug’s development and potential use in clinical settings.
Background on Contezolid and MRX-4
Contezolid was approved in China in June 2021 for the treatment of complex skin and soft tissue infections. MRX-4, also known as contezolid acefosamil, is the pro-drug version of contezolid (MRX-1), a potent oxazolidinone antibiotic effective against Gram-positive pathogens. The MRX-4/contezolid combination has been previously approved for use as a sequential treatment for infections caused by drug-resistant Gram-positive bacteria in multiple countries, including for diabetic foot infection.-Fineline Info & Tech
Leave a Reply